Literature DB >> 15337500

Carnitine deficiency in children and adolescents with type 1 diabetes.

Dimitrios Mamoulakis1, Emmanouil Galanakis, Eva Dionyssopoulou, Athanassios Evangeliou, Stelios Sbyrakis.   

Abstract

Carnitine is essential for the lipid and carbohydrate metabolism, and proper metabolic control in type 1 diabetes has potential impact on long-term complications. The plasma total, free, and acylcarnitine levels in 47 children and adolescents with type 1 diabetes were determined by a radioisotopic assay and compared to the values of a series of anthropometric measurements and metabolic parameters, including blood glycosylated hemoglobin Alc, serum cholesterol and triglycerides, and urine microalbumin levels. Plasma values for total, free, and acylcarnitine were 30.1+/-7.26, 20.0+/-4.50, and 10.2+/-6.47 micromol/l, respectively. Acyl/free carnitine ratio was 0.544+/-0.369. Individuals with type 1 diabetes had significantly lower total and free carnitine levels and significantly higher acyl/free carnitine ratios than controls (P<.001). Plasma total and free carnitine levels were inversely correlated to the duration of diabetes (P=.036 and P=.071, respectively). No statistical relationship was documented between carnitine levels and the remaining anthropometric and metabolic variables. In conclusion, total and free carnitine levels are decreased in children and adolescents with type 1 diabetes. This reduction is time related and may have potential interactions with the long-term complications of type 1 diabetes. Larger studies are required for final conclusions to be drawn on the precise role of carnitine and the possible benefit, if any, of carnitine supplementation in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337500     DOI: 10.1016/S1056-8727(03)00091-6

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  15 in total

1.  Effects of amino acid supplementation on myocardial cell damage and cardiac function in diabetes.

Authors:  Paramjit S Tappia; James Thliveris; Yan-Jan Xu; Nina Aroutiounova; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2011

Review 2.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

3.  The protective effect of L-carnitine on ischemia-reperfusion heart.

Authors:  Jiang Xie; Qiutang Zeng; Le Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 4.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

5.  Noninvasive assessment of exercise-related intramyocellular acetylcarnitine in euglycemia and hyperglycemia in patients with type 1 diabetes using ¹H magnetic resonance spectroscopy: a randomized single-blind crossover study.

Authors:  Andreas Boss; Roland Kreis; Stefan Jenni; Michael Ith; Jean-Marc Nuoffer; Emanuel Christ; Chris Boesch; Christoph Stettler
Journal:  Diabetes Care       Date:  2010-10-26       Impact factor: 19.112

6.  Phospholipid Levels at Seroconversion Are Associated With Resolution of Persistent Islet Autoimmunity: The Diabetes Autoimmunity Study in the Young.

Authors:  Patrick M Carry; Lauren A Vanderlinden; Randi K Johnson; Teresa Buckner; Oliver Fiehn; Andrea K Steck; Katerina Kechris; Ivana Yang; Tasha E Fingerlin; Marian Rewers; Jill M Norris
Journal:  Diabetes       Date:  2021-04-16       Impact factor: 9.337

7.  Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats.

Authors:  John I Malone; David D Cuthbertson; Michael A Malone; Douglas D Schocken
Journal:  Cardiovasc Diabetol       Date:  2006-01-19       Impact factor: 9.951

8.  Evidence for the association of the SLC22A4 and SLC22A5 genes with type 1 diabetes: a case control study.

Authors:  Jose Luis Santiago; Alfonso Martínez; Hermenegildo de la Calle; Miguel Fernández-Arquero; M Angeles Figueredo; Emilio G de la Concha; Elena Urcelay
Journal:  BMC Med Genet       Date:  2006-06-23       Impact factor: 2.103

9.  Characterization of Exosomal SLC22A5 (OCTN2) carnitine transporter.

Authors:  Lara Console; Mariafrancesca Scalise; Annamaria Tonazzi; Nicola Giangregorio; Cesare Indiveri
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

10.  Children who develop type 1 diabetes early in life show low levels of carnitine and amino acids at birth: does this finding shed light on the etiopathogenesis of the disease?

Authors:  G la Marca; S Malvagia; S Toni; B Piccini; V Di Ciommo; G F Bottazzo
Journal:  Nutr Diabetes       Date:  2013-10-28       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.